(EMAILWIRE.COM, December 15, 2009 ) Dallas, TX
Starlims Technologies Limited (NASDAQ:LIMS) soared 43% to $13.62 in the post-market session. Yesterday, lately Abbott Laboratories said late Monday it has reached an agreement to acquire Starlims Technologies Ltd., a provider of laboratory information management systems, for $123 million in cash, or $14 a share. Abbott said the deal will enhance its position in the global diagnostics market. The transaction doesn’t impact Abbott’s previously issued earnings forecast for 2009, said Abbott. The deal for Israel-based Starlims is expected to close in the first quarter of 2010.
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA)jumped 15.72% to $2.65 after it announced that it has submitted its New Drug Application (NDA) for Staccato loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004 is an inhalation product candidate being developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder. The IND for Staccato loxapine was filed with the FDA in August 2005.
JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) rose 6.42% to $5.64 in the afterhours session. For the fourth quarter, JA Solar expects shipments to exceed 210 megawatts, topping its previous expectations of a range of 170 to 200 MW. For 2009, JA Solar expects shipments for 2009 to surpass 488 MW, which represents nearly the same amount of power that a traditional coal-fired power plant generates. It also announced that its Board of Directors has approved a share repurchase program, effective December 14, 2009. Under this program, the Company is approved to repurchase up to an aggregate of $75 million of its American Depositary Shares, or ADSs, representing its ordinary shares.
ABOUT http://www.PennyStockPickalert.com
If you are planning to invest into Stock Market then you can subscribe to Free Stock Newsletter and Alerts. We are a leading stock web site that provides free stock alerts on hot penny stocks that are poised to make big gains. We also tracks small cap penny stocks that could be on the brink of a massive breakout.
PennyStockPickAlert.com
Robert Wilson
214-556-6798
info@pennystockpickalert.com
Source: EmailWire.Com
SADIF Analytics releases new summary due diligence report for Abbott Laboratories Ilhavo, Portugal – 20/10/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Abbott Laboratories (ABT). The report uses SADIF's powerful StockMarks™ stock rating... |
Abbott to Buy Visiogen For $400 Million September 3, 2009 (FinancialWire) Abbott (NYSE: ABT) said it has signed a definitive agreement to acquire privately-held Visiogen, Inc. for $400 million in cash. Irvine, California-based Visiogen, which... |
Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets Impax Laboratories, Inc. (NASDAQ:IPXL) today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic... |
Biotech Stocks Surge in Morning Session (FACT, ITMN, AMLN, CYCC, VNDA, ISIS, EXAS) (EMAILWIRE.COM, March 10, 2010 ) Dallas, Tx - InterMune, Inc. (NASDAQ:ITMN) soared 64.42% to $38.31. The stock today also touched a new 52 week high at $39.50. A panel meeting of the Food and Drug... |
Year High Stocks – NASDAQ: FACT, ITMN, BRCM (EMAILWIRE.COM, March 10, 2010 ) Dallas, Tx - InterMune, Inc. (NASDAQ:ITMN) hits a new 52-week high at $39.50 and now up 64.03% and trades at $38.21. A panel meeting of the Food and Drug Administration... |
Healthcare Stocks Mostly Mixed (ANX, AMLN, ABT, HOLX, BSX) (EMAILWIRE.COM, March 13, 2010 ) Dallas, Tx - ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) added 13.33% to $0.238 on 30.54 million shares after the company announced that the U.S. Food and Drug Administration... |
